Comparative effects between fucoxanthinol and its precursor fucoxanthin on viability and apoptosis of breast cancer cell lines MCF-7 and MDA-MB-231

Anticancer Research

Volumn 35, Issue 1, 2015, Pages 207-220

  Rwigemera, Arlette ^a   Mamelona, Jean ^a   Martin, Luc J ^a  

^a UNIVERSITÉ DE MONCTON   (Canada)

Author keywords

Fucoxanthin; Fucoxanthinol; MCF 7; MDA MB 231; NF B; SOX9

Indexed keywords

ALPHA TUBULIN; ANTINEOPLASTIC AGENT; CAROTENOID; FUCOXANTHIN; FUCOXANTHINOL; MESSENGER RNA; NUCLEOLIN; PROTEIN P52; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; TRANSCRIPTION FACTOR SOX9; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; BETA CAROTENE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SOX9 PROTEIN, HUMAN; XANTHOPHYLL;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL VIABILITY; CELL VIABILITY ASSAY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MCF 7 CELL LINE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; BREAST TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; COMPARATIVE STUDY; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BETA CAROTENE; BREAST NEOPLASMS; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; NF-KAPPA B; SOX9 TRANSCRIPTION FACTOR; XANTHOPHYLLS;

EID: 84920482331     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (85)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Matsuno T: Aquatic animal carotenoids. Fish Sci 67: 771-783, 2001.
3. Beppu F, Niwano Y, Tsukui T, Hosokawa M and Miyashita K: Single and repeated oral dose toxicity study of fucoxanthin (FX), a marine carotenoid, in mice. J Toxicol Sci 34: 501-510, 2009.
4. Beppu F, Niwano Y, Sato E, Kohno M, Tsukui T, Hosokawa M and Miyashita K: In vitro and in vivo evaluation of mutagenicity of fucoxanthin (FX) and its metabolite fucoxanthinol (FXOH). J Toxicol Sci 34: 693-698, 2009.
5. Sugawara T, Baskaran V, Tsuzuki W and Nagao A: Brown algae fucoxanthin is hydrolyzed to fucoxanthinol during absorption by Caco-2 human intestinal cells and mice. J Nutr 132: 946-951, 2002.
6. Asai A, Sugawara T, Ono H and Nagao A: Biotransformation of fucoxanthinol into amarouciaxanthin A in mice and HepG2 cells: formation and cytotoxicity of fucoxanthin metabolites. Drug Metab Dispos Biol Fate Chem 32: 205-211, 2004.
7. Nishino H, Murakoshi M, Tokuda H and Satomi Y: Cancer prevention by carotenoids. Arch Biochem Biophys 483: 165-168, 2009.
8. Nishikawa S, Hosokawa M and Miyashita K: Fucoxanthin promotes translocation and induction of glucose transporter 4 in skeletal muscles of diabetic/obese KK-A(y) mice. Phytomedicine Int J Phytother Phytopharm 19: 389-394, 2012.
9. Maeda H, Hosokawa M, Sashima T and Miyashita K: Dietary combination of fucoxanthin and fish oil attenuates the weight gain of white adipose tissue and decreases blood glucose in obese/diabetic KK-Ay mice. J Agric Food Chem 55: 7701-7706, 2007.
10. Maeda H, Hosokawa M, Sashima T, Funayama K and Miyashita K: Fucoxanthin from edible seaweed, Undaria pinnatifida, shows antiobesity effect through UCP1 expression in white adipose tissues. Biochem Biophys Res Commun 332: 392-397, 2005.
11. Kim K-N, Heo S-J, Yoon W-J, Kang S-M, Ahn G, Yi T-H and Jeon Y-J: Fucoxanthin inhibits the inflammatory response by suppressing the activation of NF-κB and MAPKs in lipopolysaccharide-induced RAW 264.7 macrophages. Eur J Pharmacol 649: 369-375, 2010.
12. Shiratori K, Ohgami K, Ilieva I, Jin XH, Koyama Y, Miyashita K, Yoshida K, Kase S and Ohno S: Effects of fucoxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. Exp Eye Res 81: 422-428, 2005.
13. Zhang S, Hunter DJ, Forman MR, Rosner BA, Speizer FE, Colditz GA, Manson JE, Hankinson SE and Willett WC: Dietary carotenoids and vitamins A, C, and E and risk of breast cancer. J Natl Cancer Inst 91: 547-556, 1999.
14. Slattery ML, Benson J, Curtin K, Ma KN, Schaeffer D and Potter JD: Carotenoids and colon cancer. Am J Clin Nutr 71: 575-582, 2000.
15. Le Marchand L, Hankin JH, Kolonel LN, Beecher GR, Wilkens LR and Zhao LP: Intake of specific carotenoids and lung cancer risk. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 2: 183-187, 1993.
16. Das SK, Hashimoto T, Shimizu K, Yoshida T, Sakai T, Sowa Y, Komoto A and Kanazawa K: Fucoxanthin induces cell cycle arrest at G0/G1 phase in human colon carcinoma cells through up-regulation of p21WAF1/Cip1. Biochim Biophys Acta 1726: 328-335, 2005.
17. Kotake-Nara E, Asai A and Nagao A: Neoxanthin and fucoxanthin induce apoptosis in PC-3 human prostate cancer cells. Cancer Lett 220: 75-84, 2005.
18. Cogswell PC, Guttridge DC, Funkhouser WK and Baldwin AS Jr: Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 19: 1123-1131, 2000.
19. Dejardin E, Bonizzi G, Bellahcene A, Castronovo V, Merville MP and Bours V: Highly-expressed p100/p52 (NFKB2) sequesters other NF-kappa B-related proteins in the cytoplasm of human breast cancer cells. Oncogene 11: 1835-1841, 1995.
20. Wang CY, Cusack JC, Liu R and Baldwin AS: Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5: 412-417, 1999.
21. Wang CY, Mayo MW and Baldwin AS: TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NFkappaB. Science 274: 784-787, 1996.
22. Hayden MS and Ghosh S: Signaling to NF-kappaB. Genes Dev 18: 2195-2224, 2004.
23. Beg AA and Baldwin AS Jr.: The I kappa B proteins: multifunctional regulators of Rel/NF-kappa B transcription factors. Genes Dev 7: 2064-2070, 1993.
24. Ghosh S, May MJ and Kopp EB: NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16: 225-260, 1998.
25. Karin M: How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene 18: 6867-6874, 1999.
26. Karin M and Ben-Neriah Y: Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18: 621-663, 2000.
27. Pahl HL: Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18: 6853-6866, 1999.
28. Baker RG, Hayden MS and Ghosh S: NF-κB, inflammation, and metabolic disease. Cell Metab 13: 11-22, 2011.
29. Kumar A, Takada Y, Boriek AM and Aggarwal BB: Nuclear factor-kappaB: its role in health and disease. J Mol Med Berl Ger 82: 434-448, 2004.
30. Zubair A and Frieri M: Role of nuclear factor-κB in breast and colorectal cancer. Curr Allergy Asthma Rep 13: 44-49, 2013.
31. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr and Sledge GW Jr.: Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17: 3629-3639, 1997.
32. Fan Y, Dutta J, Gupta N, Fan G and Gelinas C: Regulation of programmed cell death by NF-kappaB and its role in tumorigenesis and therapy. Adv Exp Med Biol 615: 223-250, 2008.
33. Biswas DK, Singh S, Shi Q, Pardee AB and Iglehart JD: Crossroads of estrogen receptor and NF-kappaB signaling. Sci STKE Signal Transduct Knowl Environ 2005: pe27, 2005.
34. Frasor J, Weaver A, Pradhan M, Dai Y, Miller LD, Lin C-Y and Stanculescu A: Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. Cancer Res 69: 8918-8925, 2009.
35. Kalaitzidis D and Gilmore TD: Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trends Endocrinol Metab TEM 16: 46-52, 2005.
36. Matheu A, Collado M, Wise C, Manterola L, Cekaite L, Tye AJ, Canamero M, Bujanda L, Schedl A, Cheah KS, Skotheim RI, Lothe RA, Lopez de Munain A, Briscoe J, Serrano M and Lovell- Badge R: Oncogenicity of the developmental transcription factor Sox9. Cancer Res 72: 1301-1315, 2012.
37. Lefebvre V, Li P and de Crombrugghe B: A new long form of Sox5 (L-Sox5), Sox6 and Sox9 are coexpressed in chondrogenesis and cooperatively activate the type II collagen gene. EMBO J 17: 5718-5733, 1998.
38. Lefebvre V, Huang W, Harley VR, Goodfellow PN and de Crombrugghe B: SOX9 is a potent activator of the chondrocytespecific enhancer of the pro alpha1(II) collagen gene. Mol Cell Biol 17: 2336-2346, 1997.
39. Hanley NA, Hagan DM, Clement-Jones M, Ball SG, Strachan T, Salas-Cortes L, McElreavey K, Lindsay S, Robson S, Bullen P, Ostrer H and Wilson DI: SRY, SOX9, and DAX1 expression patterns during human sex determination and gonadal development. Mech Dev 91: 403-407, 2000.
40. Koopman P: Sry and Sox9: mammalian testis-determining genes. Cell Mol Life Sci CMLS 55: 839-856, 1999.
41. Bernard P, Tang P, Liu S, Dewing P, Harley VR and Vilain E: Dimerization of SOX9 is required for chondrogenesis, but not for sex determination. Hum Mol Genet 12: 1755-1765, 2003.
42. Sumi E, Iehara N, Akiyama H, Matsubara T, Mima A, Kanamori H, Fukatsu A, Salant DJ, Kita T, Arai H and Doi T: SRY-related HMG box 9 regulates the expression of Col4a2 through transactivating its enhancer element in mesangial cells. Am J Pathol 170: 1854-1864, 2007.
43. Afonja O, Raaka BM, Huang A, Das S, Zhao X, Helmer E, Juste D and Samuels HH: RAR agonists stimulate SOX9 gene expression in breast cancer cell lines: evidence for a role in retinoid-mediated growth inhibition. Oncogene 21: 7850-7860, 2002.
44. Panda DK, Miao D, Lefebvre V, Hendy GN and Goltzman D: The transcription factor SOX9 regulates cell cycle and differentiation genes in chondrocytic CFK2 cells. J Biol Chem 276: 41229-41236, 2001.
45. Rwigemera A, Mamelona J and Martin LJ: Inhibitory effects of fucoxanthinol on the viability of human breast cancer cell lines MCF-7 and MDA-MB-231 are correlated with modulation of the NF-kappaB pathway. Cell Biol Toxicol 30: 157-167, 2014.
46. Schreiber E, Matthias P, Muller MM and Schaffner W: Rapid detection of octamer binding proteins with "mini-extracts", prepared from a small number of cells. Nucleic Acids Res 17: 6419, 1989.
47. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
48. Nakshatri H and Goulet RJ Jr.: NF-kappaB and breast cancer. Curr Probl Cancer 26: 282-309, 2002.
49. Wu JT and Kral JG: The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Surg Res 123: 158-169, 2005.
50. Zhou Y, Eppenberger-Castori S, Eppenberger U and Benz CC: The NFkappaB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer 12(Suppl 1): S37-S46, 2005.
51. Saegusa M, Hashimura M, Suzuki E, Yoshida T and Kuwata T: Transcriptional up-regulation of Sox9 by NF-κB in endometrial carcinoma cells, modulating cell proliferation through alteration in the p14(ARF)/p53/p21(WAF1) pathway. Am J Pathol 181: 684- 692, 2012.
52. Sun L, Mathews LA, Cabarcas SM, Zhang X, Yang A, Zhang Y, Young MR, Klarmann KD, Keller JR and Farrar WL: Epigenetic Regulation of SOX9 by the NF-κB Signaling Pathway in Pancreatic Cancer Stem Cells. Stem Cells 31: 1454-1466, 2013.
53. Malki S, Nef S, Notarnicola C, Thevenet L, Gasca S, Mejean C, Berta P, Poulat F and Boizet-Bonhoure B: Prostaglandin D2 induces nuclear import of the sex-determining factor SOX9 via its cAMP-PKA phosphorylation. EMBO J 24: 1798-1809, 2005.
54. Malki S, Boizet-Bonhoure B and Poulat F: Shuttling of SOX proteins. Int J Biochem Cell Biol 42: 411-416, 2010.
55. Kang S-I, Ko H-C, Shin H-S, Kim H-M, Hong Y-S, Lee N-H and Kim S-J: Fucoxanthin exerts differing effects on 3T3-L1 cells according to differentiation stage and inhibits glucose uptake in mature adipocytes. Biochem Biophys Res Commun 409: 769-774, 2011.
56. Liu C-L, Lim Y-P and Hu M-L: Fucoxanthin enhances cisplatininduced cytotoxicity via NFκB-mediated pathway and downregulates DNA repair gene expression in human hepatoma HepG2 cells. Mar Drugs 11: 50-66, 2013.
57. Yamamoto K, Ishikawa C, Katano H, Yasumoto T and Mori N: Fucoxanthin and its deacetylated product, fucoxanthinol, induce apoptosis of primary effusion lymphomas. Cancer Lett 300: 225- 234, 2011.
58. Konishi I, Hosokawa M, Sashima T, Kobayashi H and Miyashita K: Halocynthiaxanthin and fucoxanthinol isolated from Halocynthia roretzi induce apoptosis in human leukemia, breast and colon cancer cells. Comp Biochem Physiol Toxicol Pharmacol CBP 142: 53-59, 2006.
59. Rokkaku T, Kimura R, Ishikawa C, Yasumoto T, Senba M, Kanaya F and Mori N: Anticancer effects of marine carotenoids, fucoxanthin and its deacetylated product, fucoxanthinol, on osteosarcoma. Int J Oncol 43: 1176-1186, 2013.
60. Yoshiko S and Hoyoku N: Fucoxanthin, a natural carotenoid, induces G1 arrest and GADD45 gene expression in human cancer cells. In Vivo 21: 305-309, 2007.
61. Kotake-Nara E, Kushiro M, Zhang H, Sugawara T, Miyashita K and Nagao A: Carotenoids affect proliferation of human prostate cancer cells. J Nutr 131: 3303-3306, 2001.
62. Kotake-Nara E, Terasaki M and Nagao A: Characterization of apoptosis induced by fucoxanthin in human promyelocytic leukemia cells. Biosci Biotechnol Biochem 69: 224-227, 2005.
63. Hosokawa M, Kudo M, Maeda H, Kohno H, Tanaka T and Miyashita K: Fucoxanthin induces apoptosis and enhances the antiproliferative effect of the PPARgamma ligand, troglitazone, on colon cancer cells. Biochim Biophys Acta 1675: 113-119, 2004.
64. Kim K-N, Heo S-J, Kang S-M, Ahn G and Jeon Y-J: Fucoxanthin induces apoptosis in human leukemia HL-60 cells through a ROSmediated Bcl-xL pathway. Toxicol Vitro Int J Publ Assoc BIBRA 24: 1648-1654, 2010.
65. Liu C-L, Huang Y-S, Hosokawa M, Miyashita K and Hu M-L: Inhibition of proliferation of a hepatoma cell line by fucoxanthin in relation to cell cycle arrest and enhanced gap junctional intercellular communication. Chem Biol Interact 182: 165-172, 2009.
66. Satomi Y and Nishino H: Implication of mitogen-activated protein kinase in the induction of G1 cell cycle arrest and gadd45 expression by the carotenoid fucoxanthin in human cancer cells. Biochim Biophys Acta 1790: 260-266, 2009.
67. Gumpricht E, Dahl R, Devereaux MW and Sokol RJ: Betacarotene prevents bile acid-induced cytotoxicity in the rat hepatocyte: Evidence for an antioxidant and anti-apoptotic role of beta-carotene in vitro. Pediatr Res 55: 814-821, 2004.
68. Biswas DK, Cruz AP, Gansberger E and Pardee AB: Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA 97: 8542-8547, 2000.
69. Biswas DK, Dai SC, Cruz A, Weiser B, Graner E and Pardee AB: The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers. Proc Natl Acad Sci USA 98: 10386-10391, 2001.
70. Viatour P, Merville M-P, Bours V and Chariot A: Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci 30: 43-52, 2005.
71. Lee J-Y, Lee M-S, Choi H-J, Choi JW, Shin T, Woo HC, Kim JI and Kim HR: Hexane fraction from Laminaria japonica exerts anti-inflammatory effects on lipopolysaccharide-stimulated RAW 264.7 macrophages via inhibiting NF-kappaB pathway. Eur J Nutr 52: 409-421, 2013.
72. Zhu L, Zhu B, Yang L, Zhao X, Jiang H and Ma F: RelB regulates Bcl-xl expression and the irradiation-induced apoptosis of murine prostate cancer cells. Biomed Rep 2: 354-358, 2014.
73. Kang DW, Lee JY, Oh DH, Park SY, Woo TM, Kim MK, Park MH, Jang YH and Min do S: Triptolide-induced suppression of phospholipase D expression inhibits proliferation of MDA-MB- 231 breast cancer cells. Exp Mol Med 41: 678-685, 2009.
74. Kannaiyan R, Manu KA, Chen L, Li F, Rajendran P, Subramaniam A, Lam P, Kumar AP and Sethi G: Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K/Akt signaling pathways. Apoptosis Int J Program Cell Death 16: 1028-1041, 2011.
75. Liu J, Jiang Z, Xiao J, Zhang Y, Lin S, Duan W, Yao J, Liu C, Huang X, Wang T, Liang Z, Wang R, Zhang S and Zhang L: Effects of triptolide from Tripterygium wilfordii on ERalpha and p53 expression in two human breast cancer cell lines. Phytomedicine Int J Phytother Phytopharm 16: 1006-1013, 2009.
76. Chakravarty G, Moroz K, Makridakis NM, Lloyd SA, Galvez SE, Canavello PR, Lacey MR, Agrawal K and Mondal D: Prognostic significance of cytoplasmic SOX9 in invasive ductal carcinoma and metastatic breast cancer. Exp Biol Med Maywood NJ 236: 145-155, 2011.
77. Bellizzi A, Mangia A, Chiriatti A, Petroni S, Quaranta M, Schittulli F, Malfettone A, Cardone RA, Paradiso A and Reshkin SJ: RhoA protein expression in primary breast cancers and matched lymphocytes is associated with progression of the disease. Int J Mol Med 22: 25-31, 2008.
78. Katoh M: Cancer genomics and genetics of FGFR2 (Review). Int J Oncol 33: 233-237, 2008.
79. Kubo M, Nakamura M, Tasaki A, Yamanaka N, Nakashima H, Nomura M, Kuroki S and Katano M: Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res 64: 6071-6074, 2004.
80. Moore LD, Isayeva T, Siegal GP and Ponnazhagan S: Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo. Clin Cancer Res Off J Am Assoc Cancer Res 14: 4961-4970, 2008.
81. Xu Z, Wang W, Deng C-X and Man Y-G: Aberrant p63 and WT- 1 expression in myoepithelial cells of pregnancy-associated breast cancer: implications for tumor aggressiveness and invasiveness. Int J Biol Sci 5: 82-96, 2009.
82. Zardawi SJ, O'Toole SA, Sutherland RL and Musgrove EA: Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer. Histol Histopathol 24: 385-398, 2009.
83. Chakravarty G, Rider B and Mondal D: Cytoplasmic compartmentalization of SOX9 abrogates the growth arrest response of breast cancer cells that can be rescued by trichostatin A treatment. Cancer Biol Ther 11: 71-83, 2011.
84. Han J, Jogie-Brahim S, Harada A and Oh Y: Insulin-like growth factor-binding protein-3 suppresses tumor growth via activation of caspase-dependent apoptosis and cross-talk with NF-κB signaling. Cancer Lett 307: 200-210, 2011.
85. Zhang Z, Kakutani K, Maeno K, Takada T, Yurube T, Doita M, Kurosaka M and Nishida K: Expression of silent mating type information regulator 2 homolog 1 and its role in human intervertebral disc cell homeostasis. Arthritis Res Ther 13: R200, 2011.